Sarah Watson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sarah Watson has a total of 463 co-authors. Here are the top co-authors by number of shared publications:
- Sylvie Bonvalot
Department of Surgical Oncology, Institut Curie, Paris, France
9 shared publications Sophie El Zein
Département de Médecine Diagnostique et Théranostique Institut Curie, PSL Research University Paris France
7 shared publicationsDimitri Tzanis
Department of Surgical Oncology Institut Curie, PSL Research University Paris France
6 shared publications- Jean-Yves Blay
Medical Oncology Department Centre Léon Bérard Lyon France
5 shared publications - Maud Toulmonde
Department of Medical Oncology Institut Bergonié Bordeaux France
4 shared publications - Sophie El Zein
Department of Biopathology, Institute Curie, Paris, France
4 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by Wiley in International Journal of Cancer
Descriptive Analysis of Epidemiology, Demographic Characteristics, and Survival of Dedifferentiated Liposarcoma in France
Dedifferentiated liposarcoma (DDLPS) is a rare soft tissue sarcoma with limited real‐world epidemiologic data. This nationwide retrospective study describes the epidemiology, management, and outcomes of DDLPS in France using the NETSARC+ national sarcoma registry. A total of 1451 adults with histologically confirmed DDLPS diagnosed between 2010 and 2021 across 14 expert centers were included. The median age at diagnosis was 67 years, with a male predominance (M/F ratio 1.84). The retroperitoneum was the most frequent site (51.6%), and tumors were large (median 150 mm) and FNCLCC Grade 2–3 in 82.6%. MDM2 amplification was confirmed in 97.4% of tested cases. Surgery was performed in 91% of localized cases and was the strongest independent prognostic factor for overall survival (OS). After a median follow‐up of 78.4 months, median OS was 90.3 months (95% CI 82.7–101.0). Among metastatic patients, the median first‐line progression‐free survival (PFS1) was 4.1 months, and second‐line PFS (PFS2) was 3.1 months, with stable disease as the most common best response (40.6%) and 12% of partial response. Doxorubicin‐based chemotherapy remained the predominant systemic treatment but yielded only modest activity, with no difference compared to other regimens in terms of response rate. Independent predictors of improved OS included younger age, smaller tumor size, good performance status, lower grade and absence of metastasis at diagnosis. This large, population‐based study provides the most comprehensive real‐world characterization of DDLPS in France, validating known prognostic factors, emphasizing the central role of surgery, and underscoring the persistent and unmet need for more effective systemic therapies.
- 3 November 2026
- Published by Wiley in International Journal of Cancer
Open AccessDescriptive Analysis of Epidemiology, Demographic Characteristics, and Survival of Dedifferentiated Liposarcoma in France
Dedifferentiated liposarcoma (DDLPS) is a rare soft tissue sarcoma with limited real‐world epidemiologic data. This nationwide retrospective study describes the epidemiology, management, and outcomes of DDLPS in France using the NETSARC+ national sarcoma registry. A total of 1451 adults with histologically confirmed DDLPS diagnosed between 2010 and 2021 across 14 expert centers were included. The median age at diagnosis was 67 years, with a male predominance (M/F ratio 1.84). The retroperitoneum was the most frequent site (51.6%), and tumors were large (median 150 mm) and FNCLCC Grade 2–3 in 82.6%. MDM2 amplification was confirmed in 97.4% of tested cases. Surgery was performed in 91% of localized cases and was the strongest independent prognostic factor for overall survival (OS). After a median follow‐up of 78.4 months, median OS was 90.3 months (95% CI 82.7–101.0). Among metastatic patients, the median first‐line progression‐free survival (PFS1) was 4.1 months, and second‐line PFS (PFS2) was 3.1 months, with stable disease as the most common best response (40.6%) and 12% of partial response. Doxorubicin‐based chemotherapy remained the predominant systemic treatment but yielded only modest activity, with no difference compared to other regimens in terms of response rate. Independent predictors of improved OS included younger age, smaller tumor size, good performance status, lower grade and absence of metastasis at diagnosis. This large, population‐based study provides the most comprehensive real‐world characterization of DDLPS in France, validating known prognostic factors, emphasizing the central role of surgery, and underscoring the persistent and unmet need for more effective systemic therapies.
- 3 April 2026
- Published by Elsevier in Bulletin du Cancer
- Vol. 113 (7-8) , 949-952
Rôle de la Réunion de concertation pluridisciplinaire nationale dans la prise en charge diagnostique et thérapeutique des patients atteints de cancers de primitif inconnu (CAPI)
- 3 April 2026
- Published by Elsevier in Bulletin du Cancer
- Vol. 113 (7-8) , 949-952
Rôle de la Réunion de concertation pluridisciplinaire nationale dans la prise en charge diagnostique et thérapeutique des patients atteints de cancers de primitif inconnu (CAPI)
- 25 March 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 239, 116696
Liver and peritoneal metastases of unknown primary site: French Intergroup Clinical Practice guidelines for diagnosis, treatment, and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, SFP, SFR, ACHBT, SFRO, SNFCP, AFEF, RENAPE, NET-CAPI)
- 25 March 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 239, 116696
Liver and peritoneal metastases of unknown primary site: French Intergroup Clinical Practice guidelines for diagnosis, treatment, and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, SFP, SFR, ACHBT, SFRO, SNFCP, AFEF, RENAPE, NET-CAPI)
- 24 February 2026
- Published by Wiley in International Journal of Cancer
- Vol. 159 (1) , 234-243
Trabectedin in the treatment of soft tissue sarcoma: Real‐world data on effectiveness, safety, and financial implications from a European comprehensive cancer center
Soft‐tissue sarcomas (STS) comprise over 150 histological subtypes, with advanced cases showing poor prognosis (5‐year survival n = 16), soft‐tissue leiomyosarcomas ( n = 17), and myxoid liposarcomas ( n = 8). Non‐L‐sarcomas (22%) included mostly synovial sarcomas. The overall disease control rate was 71%, with a median progression‐free survival (PFS) of 4.1 months, and an overall survival of 12.3 months. Subtype‐specific median PFS was 6.8 months for liposarcomas (11.3 for myxoid vs. 4.5 for other subtypes), 3.1 months for leiomyosarcomas (3.4 months for uterine vs. 3.1 for soft‐tissue), and 2.4 months for non‐L‐sarcomas. Patients received a median of 5 cycles (range: 1–38), with an average total dose of 16 mg [2–81], and an average hospital cost of €9900. Adverse events occurred in 91%, mainly hematological; cardiac toxicity was seen in 9%. This retrospective single‐center study in a limited cohort provides real‐world insights but should be interpreted with caution. Despite limited reimbursement, trabectedin may retain clinical utility, particularly in L‐sarcoma management.
- 24 February 2026
- Published by Wiley in International Journal of Cancer
- Vol. 159 (1) , 234-243
Trabectedin in the treatment of soft tissue sarcoma: Real‐world data on effectiveness, safety, and financial implications from a European comprehensive cancer center
Soft‐tissue sarcomas (STS) comprise over 150 histological subtypes, with advanced cases showing poor prognosis (5‐year survival n = 16), soft‐tissue leiomyosarcomas ( n = 17), and myxoid liposarcomas ( n = 8). Non‐L‐sarcomas (22%) included mostly synovial sarcomas. The overall disease control rate was 71%, with a median progression‐free survival (PFS) of 4.1 months, and an overall survival of 12.3 months. Subtype‐specific median PFS was 6.8 months for liposarcomas (11.3 for myxoid vs. 4.5 for other subtypes), 3.1 months for leiomyosarcomas (3.4 months for uterine vs. 3.1 for soft‐tissue), and 2.4 months for non‐L‐sarcomas. Patients received a median of 5 cycles (range: 1–38), with an average total dose of 16 mg [2–81], and an average hospital cost of €9900. Adverse events occurred in 91%, mainly hematological; cardiac toxicity was seen in 9%. This retrospective single‐center study in a limited cohort provides real‐world insights but should be interpreted with caution. Despite limited reimbursement, trabectedin may retain clinical utility, particularly in L‐sarcoma management.
- Open Access
- 17 February 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 237, 116590
Natural history and treatment sensitivity of alveolar soft part sarcoma: A national multicenter analysis from the French sarcoma group
- 17 February 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 237, 116590
Open AccessNatural history and treatment sensitivity of alveolar soft part sarcoma: A national multicenter analysis from the French sarcoma group
- Open Access
- 8 November 2025
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 60, 101524
Management and survival of patients with cancer of unknown primary discussed by a French national multidisciplinary tumour board: a retrospective analysis
- 8 November 2025
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 60, 101524
Open AccessManagement and survival of patients with cancer of unknown primary discussed by a French national multidisciplinary tumour board: a retrospective analysis
- 20 October 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 231, 116066
Real-world immunotherapy outcomes in unresectable peritoneal mesothelioma: A French experience
- 20 October 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 231, 116066
Real-world immunotherapy outcomes in unresectable peritoneal mesothelioma: A French experience
- Top Cited PapersOpen Access
- 7 May 2025
- Published by Springer Nature in Nature
- Vol. 642 (8067) , 492-500
Activation of lysosomal iron triggers ferroptosis in cancer
Iron catalyses the oxidation of lipids in biological membranes and promotes a form of cell death called ferroptosis1. Defining where this chemistry occurs in the cell can inform the design of drugs capable of inducing or inhibiting ferroptosis in various disease-relevant settings. Genetic approaches have revealed suppressors of ferroptosis2,3,4; by contrast, small molecules can provide spatiotemporal control of the chemistry at work5. Here we show that the ferroptosis inhibitor liproxstatin-1 exerts cytoprotective effects by inactivating iron in lysosomes. We also show that the ferroptosis inducer RSL3 initiates membrane lipid oxidation in lysosomes. We designed a small-molecule activator of lysosomal iron—fentomycin-1—to induce the oxidative degradation of phospholipids and ultimately ferroptosis. Fentomycin-1 is able to kill iron-rich CD44high primary sarcoma and pancreatic ductal adenocarcinoma cells, which can promote metastasis and fuel drug tolerance. In such cells, iron regulates cell adaptation6,7 while conferring vulnerability to ferroptosis8,9. Sarcoma cells exposed to sublethal doses of fentomycin-1 acquire a ferroptosis-resistant cell state characterized by the downregulation of mesenchymal markers and the activation of a membrane-damage response. This phospholipid degrader can eradicate drug-tolerant persister cancer cells in vitro and reduces intranodal tumour growth in a mouse model of breast cancer metastasis. Together, these results show that control of iron reactivity confers therapeutic benefits, establish lysosomal iron as a druggable target and highlight the value of targeting cell states10.
- 7 May 2025
- Published by Springer Nature in Nature
- Vol. 642 (8067) , 492-500
Top Cited PapersOpen AccessActivation of lysosomal iron triggers ferroptosis in cancer
Iron catalyses the oxidation of lipids in biological membranes and promotes a form of cell death called ferroptosis1. Defining where this chemistry occurs in the cell can inform the design of drugs capable of inducing or inhibiting ferroptosis in various disease-relevant settings. Genetic approaches have revealed suppressors of ferroptosis2,3,4; by contrast, small molecules can provide spatiotemporal control of the chemistry at work5. Here we show that the ferroptosis inhibitor liproxstatin-1 exerts cytoprotective effects by inactivating iron in lysosomes. We also show that the ferroptosis inducer RSL3 initiates membrane lipid oxidation in lysosomes. We designed a small-molecule activator of lysosomal iron—fentomycin-1—to induce the oxidative degradation of phospholipids and ultimately ferroptosis. Fentomycin-1 is able to kill iron-rich CD44high primary sarcoma and pancreatic ductal adenocarcinoma cells, which can promote metastasis and fuel drug tolerance. In such cells, iron regulates cell adaptation6,7 while conferring vulnerability to ferroptosis8,9. Sarcoma cells exposed to sublethal doses of fentomycin-1 acquire a ferroptosis-resistant cell state characterized by the downregulation of mesenchymal markers and the activation of a membrane-damage response. This phospholipid degrader can eradicate drug-tolerant persister cancer cells in vitro and reduces intranodal tumour growth in a mouse model of breast cancer metastasis. Together, these results show that control of iron reactivity confers therapeutic benefits, establish lysosomal iron as a druggable target and highlight the value of targeting cell states10.